Subcutaneous dosing of kisspeptin-10 in hypogonadotropic hypogonadism

Subcutaneous pulsatile administration of kisspeptin-10 addresses the need for HH treatment by increasing reproductive hormones and follicular development, achieving elevated LH and FSH levels and promoting dominant follicle development.

WO2026236466A1PCT designated stage Publication Date: 2026-11-12THE GENERAL HOSPITAL CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027069
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-01-28
Filing Date
2026-05-07
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

There is a need for effective treatments for hypogonadotropic hypogonadism (HH), including congenital and acquired forms such as idiopathic HH and hypothalamic amenorrhea, to stimulate reproductive hormone release and promote follicular development.

Method used

Administering kisspeptin-10 or a pharmaceutically acceptable salt thereof subcutaneously in a pulsatile manner at a dose of 0.9 pg/kg to 13.19 pg/kg, with a frequency of 1 to 4 hours, over a period of at least 14 days, to activate the reproductive axis and promote dominant ovarian follicle development.

Benefits of technology

This approach increases luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels, initiates pulsatile LH secretion, and promotes the development of a dominant ovarian follicle, leading to potential ovulation and vaginal bleeding.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000008_0001
    Figure IMGF000008_0001
  • Figure IMGF000016_0001_TABLE
    Figure IMGF000016_0001_TABLE
  • Figure IMGF000017_0001_TABLE
    Figure IMGF000017_0001_TABLE
Patent Text Reader

Abstract

The invention features methods of treating a subject having hypogonadotropic hypogonadism (HH) (e.g., congenital HH (e.g., IHH) or acquired HH (e.g., hypothalamic amenorrhea)) by subcutaneously administering a therapeutically effective amount of kisspeptin, a kisspeptin analogue, or a salt thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] PATENT

[0002] Attorney Docket No.: 51796-006WO3

[0003] MGH Ref.: 2025-018

[0004] SUBCUTANEOUS DOSING OF KISSPEPTIN-10 IN HYPOGONADOTROPIC HYPOGONADISM

[0005] SEQUENCE LISTING

[0006] The instant application contains a Sequence Listing which has been submitted electronically in XML file format and is hereby incorporated by reference in its entirety. Said XML copy, created on April 24, 2026, is named 51796-006WO3_Sequence_Listing_4_24_26.xml and is 1,765 bytes in size.

[0007] STATEMENT AS TO FEDERALLY FUNDED RESEARCH

[0008] This invention was made with government support under 1 R01 FD007843-01 and

[0009] 5R01 FD005712-04, awarded by the FDA, and under 5R37HD043341 -22, 5P50HD028138-25, and 5K24HD067388-05, awarded by the NIH. The government has certain rights in the invention.

[0010] BACKGROUND OF THE INVENTION

[0011] This application relates to treating hypogonadotropic hypogonadism (HH) (e.g., congenital HH (e.g., idiopathic HH) or acquired HH (e.g., hypothalamic amenorrhea)).

[0012] The kisspeptin receptor (KISS1R) is a member of the G protein-coupled receptor family.

[0013] Kisspeptins, the native ligands of KISS1 R, are encoded as a 145 amino acid precursor, which is proteolyzed to fragments of between 10-54 amino acids in length. The mRNA of human KISS1R is expressed abundantly in placenta, pituitary, spinal cord and pancreas, and is expressed at a low level in other tissues including different parts of brain (thalamus, caudate nucleus, substantia nigra, hippocampus, amygdala, prefrontal cortex, hypothalamus, and cerebellum), stomach, small intestine, thymus, spleen, lung, testis, kidney and fetal liver.

[0014] KISS1R signaling results in gonadotropin-releasing hormone (GnRH) release, which is required for the activation of gonadotropes at the pituitary level, and downstream release of luteinizing hormone (LH), follicle-stimulating hormone (FSH) and inhibin in males and females, estradiol and anti-mullerian hormone (AMH) in females, and testosterone in males.

[0015] There is therefore a need in the art for treatments for HH.

[0016] SUMMARY OF THE INVENTION

[0017] In one aspect, the invention features a method of treating a subject having hypogonadotropic hypogonadism (HH), the method comprising administering to the subject between about 0.9 pg / kg to about 13.19 pg / kg kisspeptin-10 or a pharmaceutically acceptable salt thereof, wherein the administration is pulsatile at a frequency of between about 1 hour to about 4 hours, wherein the pulsatile administration is subcutaneous, and wherein the pulsatile administration is over a period of at least 14 days.

[0018] In some embodiments, the subject is a male.

[0019] In some embodiments, the subject is a female.

[0020] In some embodiments, the HH is congenital HH. In some embodiments, the congenital HH is idiopathic HH (IHH). In some embodiments, the IHH is Kallmann syndrome.

[0021] In some embodiments, the HH is acquired HH. In some embodiments, the acquired HH is hypothalamic amenorrhea (HA).PATENT

[0022] Attorney Docket No.: 51796-006WO3

[0023] MGH Ref.: 2025-018

[0024] In some embodiments, the kisspeptin- 10 or a pharmaceutically acceptable salt thereof is administered at a dose of between about 3 pg / kg to about 13.19 pg / kg. In some embodiments, the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered at a dose of between about 7 pg / kg to about 13.19 pg / kg. In some embodiments, the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered at a dose of about 3 pg / kg. In some embodiments, the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered at a dose of about 7 pg / kg. In some embodiments, the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered at a dose of about 10 pg / kg. In some embodiments, the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered at a dose of about 13.19 pg / kg.

[0025] In some embodiments, the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered at a dose of between 1.5 pg / kg to about 2.5 pg / kg. In some embodiments, the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered at a dose of about 2 pg / kg.

[0026] In some embodiments, the pulsatile administration is over a period of 14 days. In some embodiments, the pulsatile administration is over a period of 15 days or longer.

[0027] In some embodiments, kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered using a pump (e.g., a programmable pump).

[0028] In some embodiments, prior to treatment with kisspeptin-10 or a pharmaceutically acceptable salt thereof, the subject is administered gonadotropin-releasing hormone (GnRH) or an agonist thereof. In some embodiments, GnRH is administered at a dose of between about 20 ng / kg to about 30 ng / kg. In some embodiments, GnRH is administered at a dose of about 25 ng / kg. In some embodiments, GnRH is administered subcutaneously using a pump. In some embodiments, GnRH is administered at a frequency of about every 2 hours. In some embodiments, GnRH is administered over a period of about 6 days.

[0029] In some embodiments, the GnRH agonist is leuprolide acetate. In some embodiments, leuprolide acetate is administered at a dose of about 0.5 mg to about 1.5 mg. In some embodiments, leuprolide acetate is administered at a dose of about 1.0 mg. In some embodiments, leuprolide acetate is administered subcutaneously. In some embodiments, leuprolide acetate is administered within about two weeks prior to treatment with kisspeptin-10 or a pharmaceutically acceptable salt thereof.

[0030] In some embodiments, administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof results in an increase in luteinizing hormone (LH) levels in the subject relative to a pre-treatment baseline LH level.

[0031] In some embodiments, administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof initiates pulsatile LH secretion in the subject.

[0032] In some embodiments, LH levels in the subject remain elevated relative to a pre-treatment baseline LH level for at least one day following cessation of administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof.

[0033] In some embodiments, administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof results in an increase in follicle-stimulating hormone (FSH) levels in the subject relative to a pre-treatment baseline FSH level.PATENT

[0034] Attorney Docket No.: 51796-006WO3

[0035] MGH Ref.: 2025-018

[0036] In some embodiments, FSH levels in the subject remain elevated relative to a pre-treatment baseline FSH level for at least one day following cessation of administration of kisspeptin- 10 or a pharmaceutically acceptable salt thereof.

[0037] In another aspect, the invention features a method for inducing follicular growth in a human female subject having HH, comprising administering kisspeptin-10 or a pharmaceutically acceptable salt thereof at a dose of between about 0.9 pg / kg to about 13.19 pg / kg, wherein the dose is sufficient to promote development of at least one dominant ovarian follicle in the human female subject.

[0038] In some embodiments, the HH is congenital HH. In some embodiments, the congenital HH is IHH. In some embodiments, the IHH is Kallmann syndrome.

[0039] In some embodiments, the HH is acquired HH. In some embodiments, the acquired HH is HA. In some embodiments, the dominant ovarian follicle produces a pre-ovulatory estradiol surge. In some embodiments, administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof results in ovulation of the dominant ovarian follicle.

[0040] In some embodiments, the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered at a dose of between about 3 pg / kg to about 13.19 pg / kg. In some embodiments, the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered at a dose of between about 7 pg / kg to about 13.19 pg / kg. In some embodiments, the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered at a dose of about 10 pg / kg.

[0041] In some embodiments, the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered at a dose of between about 1.5 pg / kg to about 2.5 pg / kg. In some embodiments, the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered at a dose of about 2 pg / kg.

[0042] In some embodiments, the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered subcutaneously.

[0043] In some embodiments, the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered using a pump.

[0044] In some embodiments, the administration is pulsatile at a frequency of between about 1 hour to about 4 hours.

[0045] In some embodiments, the administration is over a period of at least 14 days.

[0046] In some embodiments, the method further comprises monitoring follicular size and estradiol levels to adjust dosing during treatment.

[0047] In some embodiments, following administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof, the dominant ovarian follicle reaches a diameter of at least 12 mm.

[0048] In some embodiments, following administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof, the subject achieves a serum estradiol concentration of at least 300 pg / mL.

[0049] In some embodiments, following administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof, the subject exhibits vaginal bleeding.

[0050] In another aspect, the invention features a treatment kit comprising: (a) kisspeptin-10 or a pharmaceutically acceptable salt thereof; and (b) instructions for administering the kisspeptin-10 or aPATENT

[0051] Attorney Docket No.: 51796-006WO3

[0052] MGH Ref.: 2025-018

[0053] pharmaceutically acceptable salt thereof subcutaneously in a pulsatile manner at a dose of between about 0.9 pg / kg to about 13.19 pg / kg over a period of at least 14 days to treat HH.

[0054] In another aspect, the invention features kisspeptin-10 or a pharmaceutically acceptable salt thereof for use in the treatment of HH in a human subject, wherein the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered subcutaneously in a pulsatile manner at a dose of between about 0.9 pg / kg to about 13.19 pg / kg, wherein the pulsatile administration has a frequency of about 1 hour to about 4 hours, and wherein the administration is over a period of at least 14 days.

[0055] In another aspect, the invention features a use of kisspeptin-10 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of HH in a human subject, wherein the medicament is formulated for subcutaneous, pulsatile administration at a dose of between about 0.9 pg / kg to about 13.19 pg / kg, wherein the pulsatile administration has a frequency of about 1 hour to about 4 hours, and wherein the medicament is administered over a period of at least 14 days.

[0056] In another aspect, the invention features kisspeptin-10 or a pharmaceutically acceptable salt thereof for use in inducing follicular development in a human female subject having HH, wherein the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered subcutaneously in a pulsatile manner at a dose of between about 0.9 pg / kg to about 13.19 pg / kg, wherein the pulsatile administration has a frequency of about 1 hour to about 4 hours, and wherein the administration is over a period of at least 14 days, thereby promoting development of at least one dominant ovarian follicle.

[0057] In another aspect, the invention features a use of kisspeptin-10 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for inducing follicular development in a human female subject having HH, wherein the medicament is formulated for subcutaneous, pulsatile administration at a dose of between about 0.9 pg / kg to about 13.19 pg / kg, wherein the pulsatile administration has a frequency of about 1 hour to about 4 hours, and wherein administration over a period of at least 14 days promotes development of at least one dominant ovarian follicle.

[0058] In some embodiments, administration of the medicament results in a pre-ovulatory estradiol surge.

[0059] In some embodiments, following administration of the medicament, the subject achieves a serum estradiol concentration of at least 300 pg / mL.

[0060] In some embodiments, the kisspeptin-10 or a pharmaceutically acceptable salt thereof or the medicament is administered using a pump.

[0061] Other features and advantages of the invention will be apparent from the following detailed description and figures, and from the claims.

[0062] Definitions

[0063] As used herein, the term “about” refers to a value that is within 10% above or below the value being described.

[0064] As used herein, the term “kisspeptin-10” refers to a 10-amino-acid peptide including the sequence Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe (SEQ ID NO: 1).PATENT

[0065] Attorney Docket No.: 51796-006WO3

[0066] MGH Ref.: 2025-018

[0067] The term “pharmaceutically acceptable salt,” as used herein, represents salts of kisspeptin-10 described herein that are suitable for use in methods described herein. Pharmaceutically acceptable salts of kisspeptin-10 are well known in the art. For example, pharmaceutically acceptable salts are described in: Pharmaceutical Salts: Properties, Selection, and Use (Eds. P.H. Stahl and C.G. Wermuth), Wiley-VCH, 2008. The salts can be prepared in situ during the final isolation and purification of kisspeptin-10 or separately by reacting the free base group with a suitable organic acid. An exemplary pharmaceutically acceptable salt of kisspeptin-10 that may be used in the methods described herein is an acetate salt of kisspeptin-10.

[0068] As used herein, the term “treating” refers to partially or completely alleviating, ameliorating, improving, relieving, delaying onset of, inhibiting progression of, reducing severity of, and / or reducing incidence of one or more symptoms or features of a disorder. The disorder may be hypogonadotropic hypogonadism (HH) (e.g., congenital HH, such as idiopathic HH (IHH) (e.g., Kallmann syndrome), or acquired HH, such as hypothalamic amenorrhea (HA)). Treatment may be administered to a subject who does not exhibit signs of the disease and / or to a subject who exhibits only early signs of the disease for the purpose of decreasing the risk of developing pathology associated with the disease.

[0069] As used herein, the terms “subject” and “patient” are interchangeable and refer to a subject (e.g., a mammalian subject, e.g., a human subject) that receives treatment or diagnosis for a disorder as described herein. In some embodiments, the subject is a male human. In some embodiments, the subject is a female human.

[0070] As used herein, the term “pulsatile administration” refers to repeated administration of a single bolus of kisspeptin-10 or a pharmaceutically acceptable salt thereof (for example, from a pump) followed by a period of little / no release of kisspeptin-10 or a pharmaceutically acceptable salt thereof in a defined frequency. The boluses may be released at a frequency of between about 1 hour to about 4 hours (e.g., a frequency of 1.5 or 2 hours). The pulsatile administration may occur over a period of at least 14 days (e.g., a period of 14 days or a period of 15 days).

[0071] As used herein, the term "hypogonadotropic hypogonadism" (HH) refers to a condition where the subject produces little or no sex hormones due to a lack of signaling from the pituitary gland or hypothalamus.

[0072] As used herein, the term "congenital hypogonadotropic hypogonadism" (congenital HH) refers to a condition where a patient was on a trajectory since birth to never go through puberty. In some embodiments, the congenital HH may be “idiopathic HH” (IHH). In some embodiments, the IHH is normosmic, meaning that the patient has a normal ability to smell. In some embodiments, the IHH may be associated with an inability to smell, which is referred to as “Kallmann syndrome” (anosmic / hyposmic).

[0073] As used herein, the term "acquired hypogonadotropic hypogonadism" (acquired HH) refers to a postnatal onset of disorders that damage or alter the function of gonadotropin-releasing hormone (GnRH) neurons and / or pituitary gonadotroph cells. In some embodiments, the acquired HH is hypothalamic amenorrhea (HA). In some embodiments, the acquired HH is hyperprolactinemia. In some embodiments, the acquired HH may be associated with negative energy balance, malnutrition, obesity, stress, metabolicPATENT

[0074] Attorney Docket No.: 51796-006WO3

[0075] MGH Ref.: 2025-018

[0076] disorder, diabetes, acute illness, hypothyroidism, excessive exercise, analgesic or psychiatric medications, or substance abuse.

[0077] As used herein, the term “pump” refers to a medical device that delivers a therapeutic, such as kisspeptin-10 or a pharmaceutically acceptable salt thereof, to a subject in a precise manner. Pumps, such as an infusion pump, may be programmed to deliver the therapeutic subcutaneously in a pulsatile manner, such as at a frequency of about 1 hour to about 4 hours. Exemplary infusion pumps (e.g., a portable programmable pump) useful for administering kisspeptin-10 or a pharmaceutically acceptable salt thereof according to the parameters described herein include, without limitation, a Orono F portable infusion pump (Cane S.p.A, Turin, Italy) or other FDA-cleared pump, such as Eitan Medica’s AVOSET™ Infusion Pump.

[0078] As used herein, the term “dominant ovarian follicle” refers to a follicle that develops more quickly than the other follicles inside the ovary. As the dominant ovarian follicle matures, the egg housed inside will eventually be released during ovulation. Administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof as described herein may “promote development” of a dominant ovarian follicle in a human female subject, such as a human female subject having HH (e.g., IHH or HA). The development of the follicle may be assessed by determining follicle size. For example, the diameter of the follicle may be determined using any method known in the art, such as by transvaginal ultrasound.

[0079] As used herein, the term “pre-ovulatory estradiol surge” refers to an increase in estradiol that occurs in the late follicular phase of the menstrual cycle, prior to ovulation. The pre-ovulatory estradiol surge is caused by the dominant ovarian follicle's production of estradiol and signals to the brain to trigger the luteinizing hormone (LH) surge, which ultimately leads to ovulation. During the pre-ovulatory estradiol surge, subjects may exhibit a serum estradiol level of at least 100 pg / mL (e.g., at least 150 pg / mL, 200 pg / mL, 250 pg / mL, 300 pg / mL, 350 pg / mL, or 400 pg / mL).

[0080] As used herein, the term “pre-treatment baseline LH level” refers to a level of LH in a subject prior to administration of kisspeptin-10 or a pharmaceutically acceptable salt as described herein.

[0081] As used herein, the term “pre-treatment baseline FSH level” refers to a level of FSH in a subject prior to administration of kisspeptin-10 or a pharmaceutically acceptable salt as described herein.

[0082] As used herein, the term “initiates pulsatile LH secretion” indicates that, following administration of kisspeptin-10 or a pharmaceutically acceptable salt to a subject as described herein, the subject exhibits pulses of LH. In some embodiments, the subject does not exhibit pulses of LH prior to administration of kisspeptin-10 or a pharmaceutically acceptable salt. Pulsatile LH secretion may be assessed using any method known in the art, such as blood sampling.

[0083] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this disclosure belongs. For any term present in the art which is identical to any term expressly defined in this disclosure, the term's definition presented in this disclosure will control in all respects. Although methods and materials similar or equivalent to those described herein can be used in the practice of the disclosed methods and compositions, the exemplary methods and materials are described herein.PATENT

[0084] Attorney Docket No.: 51796-006WO3

[0085] MGH Ref.: 2025-018

[0086] BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a diagram of the method used in Example 1.

[0087] FIG.2 is a graph showing luteinizing hormone (LH) levels during subcutaneous, pulsatile administration of kisspeptin-10 at a dose of 10.64 pg / kg to a female subject with IHH. Experiments were performed according to the materials and methods described in Example 1.

[0088] FIG.3 is a graph showing LH levels during subcutaneous, pulsatile administration of kisspeptin-10 at a dose of 0.770 pg / kg to a male subject with IHH. Experiments were performed according to the materials and methods described in Example 1.

[0089] FIG.4 shows Patient K406’s LH levels in response to subcutaneous kisspeptin-10 boluses. Experiments were performed according to the materials and methods described in Example 2.

[0090] FIG. 5 shows Patient K406’s FSH levels in response to subcutaneous kisspeptin-10 boluses. Experiments were performed according to the materials and methods described in Example 2.

[0091] FIG.6 shows Patient K001 ’s LH levels, estradiol (E2) levels, progesterone (P4) levels, inhibin A levels, and follicle size in response to subcutaneous kisspeptin-10 boluses. Experiments were performed according to the materials and methods described in Example 3.

[0092] FIG.7 shows Patient K002’s LH levels, E2 levels, P4 levels, inhibin A levels, and follicle size in response to subcutaneous kisspeptin-10 boluses. Experiments were performed according to the materials and methods described in Example 3.

[0093] FIG.8 shows Patient K005’s LH levels, E2 levels, progesterone (PRG) levels, inhibin A levels, follicle-stimulating hormone (FSH) levels, and follicle size in response to subcutaneous kisspeptin-10 boluses. Experiments were performed according to the materials and methods described in Example 3.

[0094] FIG.9 shows Patient K006’s LH levels, E2 levels, P4 levels, inhibin A levels, and follicle size in response to subcutaneous kisspeptin-10 boluses. Experiments were performed according to the materials and methods described in Example 3.

[0095] FIG. 10 shows Patient K009’s LH levels, E2 levels, P4 levels, inhibin A levels, inhibin B levels, Anti-Mullerian hormone (AMH) levels, and follicle size in response to subcutaneous kisspeptin-10 boluses. Experiments were performed according to the materials and methods described in Example 3.

[0096] FIG. 11 shows Patient K012’s LH levels, E2 levels, P4 levels, inhibin A levels, inhibin B levels, AMH levels, and follicle size in response to subcutaneous kisspeptin-10 boluses. Experiments were performed according to the materials and methods described in Example 3.

[0097] FIG. 12 shows Patient K015’s LH levels, E2 levels, P4 levels, inhibin A levels, inhibin B levels, AMH levels, and follicle size in response to subcutaneous kisspeptin-10 boluses. Experiments were performed according to the materials and methods described in Example 3.

[0098] FIG. 13 shows Patient K017’s LH levels in response to subcutaneous kisspeptin-10 boluses. Experiments were performed according to the materials and methods described in Example 4.PATENT

[0099] Attorney Docket No.: 51796-006WO3

[0100] MGH Ref.: 2025-018

[0101] DETAILED DESCRIPTION OF THE INVENTION

[0102] The invention provides methods for treatment of hypogonadotropic hypogonadism (HH) (e.g., congenital HH or acquired HH), involving administering to the subject a therapeutically effective amount of kisspeptin-10 or a pharmaceutically acceptable salt thereof.

[0103] I. Kisspeptin-10

[0104] Kisspeptin-10 has the sequence of Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe (SEQ ID NO: 1). The structure of SEQ ID NO: 1 is shown below.

[0105] NH „ NH2

[0106] OH ..

[0107]

[0108] (SEQ ID NO: 1).

[0109] II. Methods of Treatment

[0110] The invention provides methods of treating a subject having hypogonadotropic hypogonadism (e.g., congenital HH or acquired HH), the method including administering to the subject kisspeptin-10 or a pharmaceutically acceptable salt thereof (e.g., an acetate salt of kisspeptin-10). In some embodiments, the subject is a male. In some embodiments, the subject is a female.

[0111] HH is a condition where the subject has a suppressed reproductive axis and produces little or no sex hormones due to a lack of signaling from the pituitary gland or hypothalamus. In some embodiments, the HH may be congenital HH, in which the subject was on a trajectory since birth to never go through puberty. Congenital HH may be idiopathic HH (IHH). In some embodiments, the IHH is normosmic, meaning that the patient has a normal ability to smell. In some embodiments, the IHH may be associated with an olfactory disorder such as inability to smell, which is referred to as Kallmann syndrome (anosmic / hyposmic). Patients with Kallmann syndrome may have additional developmental anomalies, such as cleft lip or hearing loss, and thus, they have a more severe phenotype than patients with IHH.

[0112] In some embodiments, the HH may be acquired HH, which refers to a postnatal onset of disorders that damage or alter the function of gonadotropin-releasing hormone (GnRH) neurons and / or pituitary gonadotroph cell. In some embodiments, the acquired HH is hypothalamic amenorrhea (HA). In some embodiments, the acquired HH is hyperprolactinemia. In some embodiments, the acquired HH may be associated with negative energy balance, malnutrition, obesity, stress, a metabolic disorder, diabetes, acute illness, hypothyroidism, excessive exercise, analgesic or psychiatric medications, or substance abuse. In some embodiments, the reproductive disorder may be abnormal pregnancy, infertility, or a reproductive disorder treated with an IVF protocol.

[0113] In some embodiments, administering kisspeptin-10 or a pharmaceutically acceptable salt to a subject having HH activates the reproductive axis. For example, administration of kisspeptin-10 or aPATENT

[0114] Attorney Docket No.: 51796-006WO3

[0115] MGH Ref.: 2025-018

[0116] pharmaceutically acceptable salt thereof to a subject having HH may elevate luteinizing hormone (LH) levels in the subject and initiate pulsatile LH secretion in the subject.

[0117] In some embodiments, administering kisspeptin-10 or a pharmaceutically acceptable salt to a subject having HH (e.g., IHH or HA) results in an increase in luteinizing hormone (LH) levels in the subject relative to a pre-treatment baseline LH level. For example, administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof to a subject having HH may result in an increase in LH levels in the subject of at least 5% (e.g., 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%) relative to a pre-treatment baseline LH level. In some embodiments, LH levels in the subject may remain elevated following cessation of administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof relative to a pre-treatment baseline LH level for at least 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 10 hours, 15 hours, 20 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 15 days, 20 days, 25 days, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, or longer.

[0118] In some embodiments, administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof to a subject having HH (e.g., IHH or HA) initiates pulsatile LH secretion in the subject. For example, following administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof to a subject having HH (e.g., IHH or HA), the subject may exhibit at least one pulse of LH (e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, or more LH pulses). In some embodiments, the subject may continue to exhibit pulsatile LH secretion following cessation of administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof. For example, following cessation of administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof, the subject may exhibit at least one pulse of LH (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, or more LH pulses).

[0119] In some embodiments, administering kisspeptin-10 or a pharmaceutically acceptable salt to a subject having HH (e.g., IHH or HA) results in an increase in follicle-stimulating hormone (FSH) levels in the subject relative to a pre-treatment baseline FSH level. For example, administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof to a subject having HH may result in an increase in FSH levels in the subject of at least 5% (e.g., 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%) relative to a pre-treatment baseline FSH level. In some embodiments, FSH levels in the subject may remain elevated following cessation of administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof relative to a pre-treatment baseline FSH level for at least 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 10 hours, 15 hours, 20 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 15 days, 20 days, 25 days, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, or longer.

[0120] In some embodiments, administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof to a subject having HH (e.g., IHH or HA) may promote development of at least one dominant ovarian follicle. Development of a dominant ovarian follicle may be assessed by determining follicle size. For example, the diameter of the follicle may be determined using any method known in the art, such as transvaginal ultrasound. In some embodiments, following administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof, the dominant ovarian follicle reaches a diameter of at least 12PATENT

[0121] Attorney Docket No.: 51796-006WO3

[0122] MGH Ref.: 2025-018

[0123] mm (e.g., 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, 20 mm, 21 mm, 22 mm, 23 mm, 24 mm, or 25 mm).

[0124] In some embodiments, the dominant ovarian follicle produces a pre-ovulatory estradiol surge. For example, a subject undergoing a pre-ovulatory estradiol surge may have a serum estradiol level of at least 100 pg / mL (e.g., at least 150 pg / mL, 200 pg / mL, 250 pg / mL, 300 pg / mL, 350 pg / mL, or 400 pg / mL). In some embodiments, administration of kisspepti n- 10 or a pharmaceutically acceptable salt thereof to a subject having HH results in ovulation of the dominant ovarian follicle.

[0125] In some embodiments, following administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof, the subject achieves a serum estradiol concentration of at least 300 pg / mL (e.g., 300 pg / mL, 310 pg / mL, 320 pg / mL, 330 pg / mL, 340 pg / mL, 350 pg / mL, 360 pg / mL, 370 pg / mL, 380 pg / mL, 390 pg / mL, or 400 pg / mL).

[0126] In some embodiments, following administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof, the subject exhibits vaginal bleeding. Vaginal bleeding in a subject, such as a subject having HH (e.g., IHH or HA), indicates that the subject has sufficient serum estradiol levels to support development of endometrial lining.

[0127] III. Dosing and Administration

[0128] To treat a subject having HH (e.g., congenital HH (e.g., IHH) or acquired HH (e.g., hypothalamic amenorrhea)), kisspeptin-10 or a pharmaceutically acceptable salt thereof may be administered in a pulsatile manner, wherein a single bolus of drug is released (for example, from a pump) followed by a period of little / no release (lag phase). This cycle occurs in a defined frequency.

[0129] In some embodiments, kisspeptin-10 or a pharmaceutically acceptable salt thereof may be administered to the subject at a dose of between about 0.9 pg / kg to about 13.19 pg / kg. For example, kisspeptin-10 or a pharmaceutically acceptable salt thereof may be administered to the subject at a dose of between about 0.9 pg / kg to about 2 pg / kg, between about 2 pg / kg to about 4 pg / kg, between about 4 pg / kg to about 6 pg / kg, between about 6 pg / kg to about 8 pg / kg, between about 8 pg / kg to about 10 pg / kg, between about 10 pg / kg to about 12 pg / kg, or between about 12 pg / kg to about 13.19 pg / kg. In another example, kisspeptin-10 or a pharmaceutically acceptable salt thereof may be administered to the subject at a dose of between about 0.81 pg / kg to about 13.19 pg / kg, between about 0.82 pg / kg to about 13.19 pg / kg, between about 0.83 pg / kg to about 13.19 pg / kg, between about 0.84 pg / kg to about 13.19 pg / kg, between about 0.85 pg / kg to about 13.19 pg / kg, between about 0.86 pg / kg to about 13.19 pg / kg, between about 0.87 pg / kg to about 13.19 pg / kg, between about 0.88 pg / kg to about 13.19 pg / kg, between about 0.89 pg / kg to about 13.19 pg / kg, or between about 0.90 pg / kg to about 13.19 pg / kg. In some embodiments, kisspeptin-10 or a pharmaceutically acceptable salt thereof may be administered to the subject at a dose of about 0.9 pg / kg, about 1 pg / kg, about 1.5 pg / kg, about 2 pg / kg, about 2.5 pg / kg, about 3 pg / kg, about 3.5 pg / kg, about 4 pg / kg, about 4.5 pg / kg, about 5 pg / kg, about 5.5 pg / kg, about 6 pg / kg, about 6.5 pg / kg, about 7 pg / kg, about 7.5 pg / kg, about 8 pg / kg, about 8.5 pg / kg, about 9 pg / kg, about 9.5 pg / kg, about 10 pg / kg, about 10.5 pg / kg, about 11 pg / kg, about 11.5 pg / kg, about 12 pg / kg, about 12.5 pg / kg, about 13 pg / kg, or about 13.19 pg / kg.PATENT

[0130] Attorney Docket No.: 51796-006WO3

[0131] MGH Ref.: 2025-018

[0132] In some embodiments, kisspeptin- 10 or a pharmaceutically acceptable salt thereof may be administered to the subject at a dose of between about 3 pg / kg to about 13.19 pg / kg. In some embodiments, kisspeptin- 10 or a pharmaceutically acceptable salt thereof may be administered to the subject at a dose of between about 7 pg / kg to about 13.19 pg / kg. In some embodiments, kisspeptin-10 or a pharmaceutically acceptable salt thereof may be administered to the subject at a dose of about 10 pg / kg (e.g., 10.26 pg / kg or 10.64 pg / kg).

[0133] In some embodiments, kisspeptin-10 or a pharmaceutically acceptable salt thereof may be administered to the subject at a dose of between about 1.5 to about 2.5 pg / kg (e.g., about 1 .5 pg / kg, about 1.6 pg / kg, about 1.7 pg / kg, about 1.8 pg / kg, about 1.9 pg / kg, about 2.0 pg / kg, about 2.1 pg / kg, about 2.2 pg / kg, about 2.3 pg / kg, about 2.4 pg / kg, or about 2.5 pg / kg). In some embodiments, kisspeptin-10 or a pharmaceutically acceptable salt thereof may be administered to the subject at a dose of about 2.0 pg / kg. In some embodiments, kisspeptin-10 or a pharmaceutically acceptable salt thereof may be administered to a human female subject at a dose sufficient to promote development of at least one dominant ovarian follicle in the human female subject.

[0134] In some embodiments, kisspeptin-10 or a pharmaceutically acceptable salt thereof may be administered to a subject having IHH at a dose of between about 3 pg / kg to about 13.19 pg / kg. In some embodiments, kisspeptin-10 or a pharmaceutically acceptable salt thereof may be administered to a subject having IHH at a dose of about 7 pg / kg to about 13.19 pg / kg. In some embodiments, kisspeptin-10 or a pharmaceutically acceptable salt thereof may be administered to a subject having IHH at a dose of about 10 pg / kg (e.g., 10.26 pg / kg or 10.64 pg / kg).

[0135] In some embodiments, kisspeptin-10 or a pharmaceutically acceptable salt thereof may be administered to a subject having hypothalamic amenorrhea at a dose of between about 1.5 to about 2.5 pg / kg (e.g., about 1.5 pg / kg, about 1 .6 pg / kg, about 1.7 pg / kg, about 1.8 pg / kg, about 1.9 pg / kg, about 2.0 pg / kg, about 2.1 pg / kg, about 2.2 pg / kg, about 2.3 pg / kg, about 2.4 pg / kg, or about 2.5 pg / kg) . In some embodiments, kisspeptin-10 or a pharmaceutically acceptable salt thereof may be administered to a subject having hypothalamic amenorrhea at a dose of about 2.0 pg / kg.

[0136] The pulsatile administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof may be at a frequency of between about 1 hour to about 4 hours (e.g., between about 1 hour to about 1.5 hours, between about 1.5 hours to about 2 hours, between about 2 hours to about 2.5 hours, between about 2.5 hours to about 3 hours, between about 3 hours to about 3.5 hours, or between about 3.5 hours to about 4 hours). In some embodiments, the pulsatile administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof may be at a frequency of about 1 hour, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, or about 4 hours. In some embodiments, the pulsatile administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof may be at a frequency of about 1.5 hours. In some embodiments, the pulsatile administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof may be at a frequency of about 2 hours.

[0137] In some embodiments, the subject is a female and the pulsatile administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof is at a frequency of about 1.5 hours. In some embodiments,PATENT

[0138] Attorney Docket No.: 51796-006WO3

[0139] MGH Ref.: 2025-018

[0140] the subject is a male and the pulsatile administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof is at a frequency of about 2 hours.

[0141] The pulsatile administration may be over a period of at least 14 days. For example, the pulsatile administration may be over a period of 14 days. In another example, the pulsatile administration may be over a period of 15 days. In another example, the pulsatile administration may be over a period of 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, or 30 days, or longer.

[0142] Kisspeptin-10 or a pharmaceutically acceptable salt thereof may be administered subcutaneously (e.g.. by a pump) to treat HH. Exemplary infusion pumps (e.g., a portable programmable pump) useful for administering kisspeptin-10 or a pharmaceutically acceptable salt thereof according to the parameters described herein include, without limitation, a Orono F portable infusion pump (Cane S.p.A, Turin, Italy) or other FDA-cleared pump, such as Eitan Medica’s AVOSET™ Infusion Pump.

[0143] In some embodiments, prior to treatment with kisspeptin-10 or a pharmaceutically acceptable salt thereof, the subject is administered gonadotropin-releasing hormone (GnRH) or an agonist thereof. The disclosure also provides for a method of treating a subject having hypogonadotropic hypogonadism (e.g., congenital HH or acquired HH), the method comprising (1) pre-treating the subject with GnRH or an agonist thereof; and (2) administering to the subject between about 0.9 pg / kg to about 13.19 pg / kg kisspeptin-10 or a pharmaceutically acceptable salt thereof, wherein the administration is pulsatile at a frequency of between about 1 hour to about 4 hours, wherein the pulsatile administration is subcutaneous, and wherein the pulsatile administration is over a period of at least 14 days.

[0144] Such pre-treatment priming involves (1) administration of GnRH or (2) administration of a GnRH agonist (e.g., leuprolide acetate, an FDA-approved GnRH agonist).

[0145] In some embodiments, the GnRH is administered at a dose of between about 20 ng / kg to about 30 ng / kg. For example, GnRH may be administered at a dose of about 25 ng / kg. In some embodiments, GnRH is administered subcutaneously using a pump (e.g., a programmable pump). In some embodiments, GnRH is administered at a frequency of about every 2 hours. In some embodiments, GnRH is administered over a period of about 6 days.

[0146] In some embodiments, the GnRH agonist is leuprolide acetate. Leuprolide acetate may be administered at a dose of about 0.5 mg to about 1.5 mg. For example, leuprolide acetate may be administered at a dose of about 1.0 mg. In some embodiments, leuprolide acetate is administered subcutaneously. In some embodiments, leuprolide acetate is administered within two weeks prior to treatment with kisspeptin-10 or a pharmaceutically acceptable salt thereof.

[0147] Other exemplary GnRH agonists suitable for use in the claimed methods include, without limitation, gonadorelin, goserelin, nafarelin, histrelin, triptorelin, or buserelin.

[0148] In some embodiments, the treating further includes monitoring follicular size and estradiol levels to adjust dosing during treatment. Follicular size and estradiol levels can be monitored using any method known in the art. For example, follicular size can be measured using a transvaginal ultrasound and estradiol levels can be measured by collecting a serum sample from the subject. If the subject’s follicle size and estradiol levels do not increase during treatment, the dose of kisspeptin-10 or a pharmaceutically acceptable salt thereof may be increased.PATENT

[0149] Attorney Docket No.: 51796-006WO3

[0150] MGH Ref.: 2025-018

[0151] EXAMPLES

[0152] The following examples are provided as a description of how the compositions and methods described herein may be used and evaluated and are intended to be purely exemplary of the invention and is not intended to limit the scope of what the inventors regard as their invention.

[0153] Example 1. Pulsatile, Subcutaneous Administration of Kisspeptin in Patients with Idiopathic Hypogonadotropic Hypogonadism

[0154] This Example describes treatment of subjects with idiopathic HH (IHH) by administering kisspeptin-10 or a pharmaceutically acceptable salt thereof.

[0155] Methods

[0156] The method is diagrammed in FIG. 1, and summarized below.

[0157] Pituitary priming

[0158] Subjects may undergo pituitary “priming” with GnRH or leuprolide acetate prior to the study visits involving frequent blood sampling. Exposure to intermittent, exogenous GnRH administration awakens or “primes” pituitary gonadotrophs in patients with long-standing hypogonadotropic hypogonadism. In lieu of using the peptide GnRH, a single dose of a GnRH agonist can also be used as these agents acutely stimulates the secretion of pituitary hormones luteinizing hormone (LH) and follicle stimulating hormone (FSH). Exemplary GnRH agonists are known in the art.

[0159] For priming with GnRH, the Orono F portable infusion pump (Cane S.p.A, Turin, Italy) may be used. Other FDA-cleared pumps may be used, as pump technology advances, to enhance subject convenience. The pump administered 25 ng / kg subcutaneously every 2 hours for about 6 days.

[0160] For priming with leuprolide acetate, a 1 mg / 0.2 mL subcutaneous kit may be used. The subject received one 1 mg subcutaneous injection of leuprolide acetate within two weeks prior to kisspeptin administration.

[0161] Pre-administration frequent blood sampling (optional)

[0162] Subjects may undergo frequent blood sampling (q10 minutes for up to 8 hours) to assess endogenous hormone secretion.

[0163] Day 1 (initiation of kisspeptin administration)

[0164] Kisspeptin-10 was administered subcutaneously (SC) in a pulsatile manner using a Crono F portable infusion pump (Cane S.p.A, Turin, Italy) which was placed in subjects according to standard procedures.

[0165] Female subjects were dosed with kisspeptin-10 at 0.313-13.19 pg / kg q60-240 minutes. This kisspeptin bolus frequency was chosen to recapitulate the normal LH pulse frequency observed in women across their menstrual cycle.PATENT

[0166] Attorney Docket No.: 51796-006WO3

[0167] MGH Ref.: 2025-018

[0168] Male subjects were dosed with kisspeptin-10 at 0.313-13.19 pg / kg q60-240 minutes.

[0169] A medical professional observed each subject for any adverse reaction during administration of the first bolus of kisspeptin. Kisspeptin continued to be administered via the pump(s) in an ambulatory and / or at-home setting.

[0170] Blood was drawn q10 minutes for up to 70 minutes. Blood sampling was timed in relation to the initial kisspeptin bolus delivered via the pump(s) to define the LH response to the kisspeptin bolus.

[0171] Days 2-15 of kisspeptin administration

[0172] Study visits were timed to allow for periodic monitoring of the subject’s response to kisspeptin. On Days 2-8, Day 10 or 11 , and Day 15, subjects had careful inspection of the pump(s) insertion site by a medical professional anytime they attended an in-person visit. Bood was drawn q10 minutes for up to 70 minutes. Blood sampling was timed in relation to a kisspeptin bolus delivered via the pump(s) to define the LH response to the kisspeptin bolus. Blood samples were assayed for reproductive hormones and proteins, as well as exploratory assays of markers of bone metabolism. Sample collection began at the same time of the day ± 3 hours from the time collection began on Day 1.

[0173] For female subjects, four pelvic ultrasounds were performed, one on Day 1 , one between Days 4-6, one on Day 10 or 11 , and one on Day 15, to monitor follicular growth and record follicle size, number and location. The first ultrasound performed after the initiation of kisspeptin administration was intended to ensure that the rate of follicular growth and number of follicles did not indicate hyperstimulation, which is considered extremely unlikely to occur based on prior data of kisspeptin administration in this dose range.

[0174] On Day 15 only, pump(s) were removed.

[0175] Post-administration frequent blood sampling (optional)

[0176] Subjects may undergo frequent blood sampling to assess endogenous hormone secretion. These visits occurred within two weeks of the end of kisspeptin administration.

[0177] Hormone assays

[0178] LH assays quantified the LH level in the blood at each time point, as a direct indicator of the degree to which kisspeptin is stimulating release of GnRH from the hypothalamus.

[0179] Results

[0180] Subcutaneous, pulsatile administration of kisspeptin-10 at a dose of 10.64 pg / kg to a female subject with IHH was sufficient to increase prevailing LH levels nearly 100% over the course of 14 days of administration, with maximal effect seen starting after 4 days of administration (FIG.2). Increased LH levels persisted after the end of kisspeptin-10 administration (seen in samples collected the day after the pump was removed).

[0181] Three patients were treated at a dose that was 10-fold lower than the dose of 10.64 pg / kg.

[0182] Subcutaneous, pulsatile administration of kisspeptin-10 at a dose of only 0.770 pg / kg (one order ofPATENT

[0183] Attorney Docket No.: 51796-006WO3

[0184] MGH Ref.: 2025-018

[0185] magnitude lower) every 120 minutes to a male subject with IHH was associated with no change in prevailing LH levels over the course of kisspeptin administration (FIG.3).

[0186] The second patient treated at a low dose was a female subject with IHH, who was treated with 1.074 pg / kg / bolus kisspeptin-10, every 90 minutes. The third patient treated at a low dose was a male subject with IHH, who was treated with 0.641 pg / kg / bolus kisspeptin-10, every 120 minutes. None of the patients treated at the lower dose responded.

[0187] Conclusion

[0188] These results demonstrate that kisspeptin-10, when administered subcutaneously in a pulsatile manner at the dose specified above, stimulates LH secretion in patients with the rare disease, IHH. Pulsatile subcutaneous kisspeptin administration at lower doses failed to stimulate the reproductive cascade according to the described dosing regimen.

[0189] Example 2. Pulsatile, Subcutaneous Administration of Kisspeptin-10 in Patients with Idiopathic Hypogonadotropic Hypogonadism

[0190] This Example describes treatment of a male subject with IHH by administering kisspeptin-10 or a pharmaceutically acceptable salt thereof with a pump for two weeks.

[0191] Methods

[0192] A male subject with IHH was administered kisspeptin-10 or a pharmaceutically acceptable salt thereof with a pump every 2 hours at a dose of 10.26 pg / kg for two weeks.

[0193] Results

[0194] LH results for each day that the patient wore the kisspeptin pump are shown in FIG.4 and FSH results for each day that the patient wore the kisspeptin pump are shown in FIG. 5. One pulse per day was monitored at the same time each morning. The first LH value for each day represents the zero time point as the patient received their kisspeptin bolus. The LH responses in FIG.4 are shown for days 1-8, 10 and 15.

[0195] The data in FIG.4 show that the patient responded to kisspeptin right away, responsiveness was maintained, and baseline LH levels at the zero time points increased over the course of the week. At the left and right ends of FIG.4 are pre-kisspeptin and post-kisspeptin LH levels, showing the male subject’s LH levels before he received any pump doses and then one day after the pump was taken off.

[0196] As shown in FIG.4, before receiving kisspeptin, the patient’s LH levels were very low, whereas after receiving kisspeptin, the patient’s LH levels are higher with pulses present.

[0197] Similar results are observed in FIG. 5 for FSH levels. The pre- and post-kisspeptin FSH levels shown at the left and right ends of FIG. 5 represent pools rather than single timepoints. FIG. 5 demonstrates that the patient responded to kisspeptin right away, responsiveness was maintained, and baseline FSH levels at the zero time points increased over the course of the week. Prior to receivingPATENT

[0198] Attorney Docket No.: 51796-006WO3

[0199] MGH Ref.: 2025-018

[0200] kisspeptin, the patient’s FSH levels were very low, whereas after receiving kisspeptin, the patient’s FSH levels increased.

[0201] Example 3. Pulsatile, Subcutaneous Administration of Kisspeptin-10 in Patients with Hypothalamic Amenorrhea

[0202] This Example describes treatment of female subjects with hypothalamic amenorrhea by administering kisspeptin- 10 or a pharmaceutically acceptable salt thereof with a pump for two weeks.

[0203] Methods

[0204] Female subjects with hypothalamic amenorrhea were administered kisspeptin- 10 or a pharmaceutically acceptable salt thereof with a pump every 90 minutes for two weeks. Dosing is summarized in Table 1, below.

[0205] Results

[0206] Results are shown in FIGS.6-12 and Table 1.

[0207] Patients receiving lower doses of kisspeptin- 10 (patients K001 , K002, and K005) had lower follicle growth and lower estrogen levels (FIGS.6-8 and Table 1). However, higher doses of kisspeptin-10 were more effective in increasing follicle size and estradiol levels. Patient K009 has a peak follicle size of 16.2 mm, which was a healthy follicle nearly at ideal size (the ideal size for a follicle in a fertility cycle is between 18 and 22 mm) (FIG. 10 and Table 1). Patient K012 had a dominant follicle of 23 mm and a peak estradiol level of 389 pg / mL (FIG. 11 and Table 1). This indicated that this follicle was not only the appropriate size but also secreting a robust amount of estrogen. Approximately 2 months after stopping the study, the patient had some vaginal bleeding. This bleeding may represent loss of the uterine lining that had been established during her time wearing the kisspeptin pump.

[0208] Accordingly, the data suggests that a dose of between 1.5 - 2 pg / kg is effective in achieving a physiologic response.

[0209] Table 1. Dosing amounts, peak estradiol, and peak follicle size.

[0210] Weight Based Dose Peak Estradiol Peak Follicle Size

[0211] Patient Notes

[0212] (pg / kg) (pg / mL) (mm)

[0213] K001 0.695 24 8.3 single pump; no Pre7Post-Admin K002 0.755 21 12 single pump; no Pre- / Post-Admin K005 1.189 24 8.8 only completed Pre- and V1 K006 1.832 41 10.2 no Pre7Post-Admin K009 1.481 62 16.2 no Pre7Post-Admin

[0214]

[0215] PATENT

[0216] Attorney Docket No.: 51796-006WO3

[0217] MGH Ref.: 2025-018

[0218] Weight Based Dose Peak Estradiol Peak Follicle Size

[0219] Patient Notes

[0220] (pg / kg) (pg / mL) (mm)

[0221] reported spotting (6 / 12 / 24); had K012 1.67 389 23

[0222] never spotted previously K015 1.224 12 7.9

[0223]

[0224] Example 4. Pulsatile, Subcutaneous Administration of Kisspeptin-10 in Patients with Hypothalamic Amenorrhea

[0225] This Example describes treatment of female subjects with hypothalamic amenorrhea by administering kisspeptin- 10 or a pharmaceutically acceptable salt thereof with a pump for two weeks.

[0226] Methods

[0227] Female subjects with hypothalamic amenorrhea were administered kisspeptin- 10 or a pharmaceutically acceptable salt thereof with a pump every 90 minutes at a dose of 2.16 pg / kg for two weeks.

[0228] Results

[0229] Results for patient K017 are shown in FIG. 13. Administration of kisspeptin-10 to the subject resulted in kisspeptin-induced LH pulses. At the beginning of the study, the subject had a 12 mm follicle, which regressed (indicating that the follicle became non-functional). However, a new follicle emerged and grew to 12 mm by the final day of the study. 31 days after the study ended, the subject experienced vaginal bleeding which is consistent with sufficient estradiol levels in the blood to support development of endometrial lining.

[0230] Example 5. Treatment of IHH in a subject by administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof

[0231] According to the methods disclosed herein, a physician of skill in the art can treat a subject having IHH. To treat the subject, a physician of skill in the art can administer to the subject kisspeptin- 10 or a pharmaceutically acceptable salt thereof.

[0232] Kisspeptin-10 or a pharmaceutically acceptable salt thereof may be administered to the subject having IHH in an amount of between about 0.9 pg / kg to about 13.19 pg / kg. For example, kisspeptin-10 or a pharmaceutically acceptable salt thereof may be administered in an amount of between about 7 pg / kg to about 13.19 pg / kg, between about 8 pg / kg to about 13.19 pg / kg, between about 9 pg / kg to about 13.19 pg / kg, between about 10 pg / kg to about 13.19 pg / kg, between about 7 pg / kg to about 12 pg / kg, between about 7 pg / kg to about 11 pg / kg, or between about 7 pg / kg to about 10 pg / kg, such as in an amount of about 7 pg / kg, about 7.5 pg / kg, about 8 pg / kg, about 8.5 pg / kg, about 9 pg / kg, about 9.5 pg / kg, about 10 pg / kg, about 10.5 pg / kg, about 11 pg / kg, about 11.5 pg / kg, about 12 pg / kg, about 12.5 pg / kg, or about 13PATENT

[0233] Attorney Docket No.: 51796-006WO3

[0234] MGH Ref.: 2025-018

[0235] Hg / kg . In some embodiments, kisspepti n- 10 or a pharmaceutically acceptable salt thereof may be administered in an amount of about 10 pg / kg (e.g., 10.26 pg / kg or 10.64 pg / kg).

[0236] Kisspeptin-10 or a pharmaceutically acceptable salt thereof may be administered to the subject having IHH in a pulsatile manner. The frequency of the pulses may be between about 1 hour to about 4 hours, such as between about 1 hour to about 1.5 hours, between about 1.5 hours to about 2 hours, between about 2 hours to about 2.5 hours, between about 2.5 hours to about 3 hours, between about 3 hours to about 3.5 hours, or between about 3.5 hours to about 4 hours. In some embodiments, the pulsatile administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof may be at a frequency of about 1 hour, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, or about 4 hours. In some embodiments, the pulsatile administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof may be at a frequency of about 1.5 hours.

[0237] Kisspeptin-10 or a pharmaceutically acceptable salt thereof may be administered in a pulsatile manner to the subject having IHH over a period of at least 14 days. For example, the pulsatile administration may be over a period of 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, or 30 days, or longer. In some embodiments, the pulsatile administration may be over a period of 14 days. In some embodiments, the pulsatile administration may be over a period of 15 days.

[0238] Kisspeptin-10 or a pharmaceutically acceptable salt thereof may be administered in a pulsatile manner to the subject having IHH subcutaneously using a pump, such as an infusion pump. Exemplary infusion pumps (e.g., a portable programmable pump) useful for administering kisspeptin-10 or a pharmaceutically acceptable salt thereof according to the parameters described herein include, without limitation, a Orono F portable infusion pump (Cane S.p.A, Turin, Italy) or other FDA-cleared pump, such as Eitan Medica’s AVOSET™ Infusion Pump.

[0239] Following administration of the composition to a patient having IHH, a practitioner of skill in the art can monitor the patient’s improvement in response to the therapy by a variety of methods. For example, a physician can monitor the patient’s luteinizing hormone (LH) levels. A finding that: (i) the patient’s LH levels have increased relative to a pre-treatment baseline LH level; (ii) the subject exhibits LH pulses; and / or (iii) LH levels in the subject remain elevated relative to a pre-treatment baseline LH level for at least one day following cessation of administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof indicates that the treatment of IHH in the patient is successful.

[0240] Additionally or alternatively, a physician can monitor the patient’s follicle-stimulating hormone (FSH) levels. A finding that: (i) the patient’s FSH levels have increased relative to a pre-treatment baseline FSH level; and / or (ii) FSH levels in the subject remain elevated relative to a pre-treatment baseline FSH level for at least one day following cessation of administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof indicates that the treatment of IHH in the patient is successful.

[0241] In some embodiments, a physician can monitor the patient’s serum estradiol concentration. A finding that the patient exhibits a pre-ovulatory estradiol surge indicates that the treatment of IHH in the patient is successful. In addition, a finding that the patient achieves a serum estradiol concentration of at least 300 pg / mL (e.g., 300 pg / mL, 310 pg / mL, 320 pg / mL, 330 pg / mL, 340 pg / mL, 350 pg / mL, 360 pg / mL,PATENT

[0242] Attorney Docket No.: 51796-006WO3

[0243] MGH Ref.: 2025-018

[0244] 370 pg / mL, 380 pg / mL, 390 pg / mL, or 400 pg / mL) indicates that the treatment of IHH in the patient is successful.

[0245] In some embodiments, a physician can monitor ovulation of the dominant ovarian follicle in the patient. A finding that the patient exhibits ovulation of the dominant ovarian follicle indicates that the treatment of IHH in the patient is successful.

[0246] In some embodiments, a physician can monitor the diameter of the patient’s dominant ovarian follicle, for example, using a transvaginal ultrasound. A finding that the patient’s dominant ovarian follicle reaches a diameter of at least 12 mm (e.g., 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, 20 mm, 21 mm, 22 mm, 23 mm, 24 mm, or 25 mm) indicates that the treatment of IHH in the patient is successful.

[0247] In some embodiments, a physician can monitor whether the subject exhibits vaginal bleeding. A finding that the patient exhibits vaginal bleeding indicates that the treatment of IHH in the patient is successful.

[0248] Example 6. Treatment of hypothalamic amenorrhea in a subject by administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof

[0249] According to the methods disclosed herein, a physician of skill in the art can treat a subject having hypothalamic amenorrhea (HA). To treat the subject, a physician of skill in the art can administer to the subject kisspeptin-10 or a pharmaceutically acceptable salt thereof.

[0250] Kisspeptin-10 or a pharmaceutically acceptable salt thereof may be administered to the subject having HA in an amount of between about 0.9 pg / kg to about 13.19 pg / kg. For example, kisspeptin-10 or a pharmaceutically acceptable salt thereof may be administered in an amount of between about 1.5 pg / kg to about 2.5 pg / kg, such as about 1.5 pg / kg, about 1.6 pg / kg, about 1.7 pg / kg, about 1.8 pg / kg, about 1.9 pg / kg, about 2.0 pg / kg, about 2.1 pg / kg, about 2.2 pg / kg, about 2.3 pg / kg, about 2.4 pg / kg, or about 2.5 pg / kg. In some embodiments, kisspeptin- 10 or a pharmaceutically acceptable salt thereof may be administered to the subject at a dose of about 2.0 pg / kg.

[0251] Kisspeptin-10 or a pharmaceutically acceptable salt thereof may be administered to the subject having HA in a pulsatile manner. The frequency of the pulses may be between about 1 hour to about 4 hours, such as between about 1 hour to about 1.5 hours, between about 1.5 hours to about 2 hours, between about 2 hours to about 2.5 hours, between about 2.5 hours to about 3 hours, between about 3 hours to about 3.5 hours, or between about 3.5 hours to about 4 hours. In some embodiments, the pulsatile administration of kisspeptin- 10 or a pharmaceutically acceptable salt thereof may be at a frequency of about 1 hour, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, or about 4 hours. In some embodiments, the pulsatile administration of kisspeptin- 10 or a pharmaceutically acceptable salt thereof may be at a frequency of about 1.5 hours.

[0252] Kisspeptin- 10 or a pharmaceutically acceptable salt thereof may be administered in a pulsatile manner to the subject having HA over a period of at least 14 days. For example, the pulsatile administration may be over a period of 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, or 30PATENT

[0253] Attorney Docket No.: 51796-006WO3

[0254] MGH Ref.: 2025-018

[0255] days, or longer. In some embodiments, the pulsatile administration may be over a period of 14 days. In some embodiments, the pulsatile administration may be over a period of 15 days.

[0256] Kisspeptin-10 or a pharmaceutically acceptable salt thereof may be administered in a pulsatile manner to the subject having HA subcutaneously using a pump, such as an infusion pump. Exemplary infusion pumps (e.g., a portable programmable pump) useful for administering kisspeptin-10 or a pharmaceutically acceptable salt thereof according to the parameters described herein include, without limitation, a Orono F portable infusion pump (Cane S.p.A, Turin, Italy) or other FDA-cleared pump, such as Eitan Medica’s AVOSET™ Infusion Pump.

[0257] Following administration of the composition to a patient having HA, a practitioner of skill in the art can monitor the patient’s improvement in response to the therapy by a variety of methods. For example, a physician can monitor the patient’s LH levels. A finding that: (i) the patient’s LH levels have increased relative to a pre-treatment baseline LH level; (ii) the subject exhibits LH pulses; and / or (iii) LH levels in the subject remain elevated relative to a pre-treatment baseline LH level for at least one day following cessation of administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof indicates that the treatment of HA in the patient is successful.

[0258] Additionally or alternatively, a physician can monitor the patient’s FSH levels. A finding that: (i) the patient’s FSH levels have increased relative to a pre-treatment baseline FSH level; and / or (ii) FSH levels in the subject remain elevated relative to a pre-treatment baseline FSH level for at least one day following cessation of administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof indicates that the treatment of HA in the patient is successful.

[0259] In some embodiments, a physician can monitor the patient’s serum estradiol concentration. A finding that the patient exhibits a pre-ovulatory estradiol surge indicates that the treatment of HA in the patient is successful. In addition, a finding that the patient achieves a serum estradiol concentration of at least 300 pg / mL (e.g., 300 pg / mL, 310 pg / mL, 320 pg / mL, 330 pg / mL, 340 pg / mL, 350 pg / mL, 360 pg / mL, 370 pg / mL, 380 pg / mL, 390 pg / mL, or 400 pg / mL) indicates that the treatment of HA in the patient is successful.

[0260] In some embodiments, a physician can monitor ovulation of the dominant ovarian follicle in the patient. A finding that the patient exhibits ovulation of the dominant ovarian follicle indicates that the treatment of HA in the patient is successful.

[0261] In some embodiments, a physician can monitor the diameter of the patient’s dominant ovarian follicle, for example, using a transvaginal ultrasound. A finding that the patient’s dominant ovarian follicle reaches a diameter of at least 12 mm (e.g., 12 mm, 13 mm, 14 mm, 15 mm, 16 mm, 17 mm, 18 mm, 19 mm, 20 mm, 21 mm, 22 mm, 23 mm, 24 mm, or 25 mm) indicates that the treatment of HA in the patient is successful.

[0262] In some embodiments, a physician can monitor whether the subject exhibits vaginal bleeding. A finding that the patient exhibits vaginal bleeding indicates that the treatment of HA in the patient is successful.PATENT

[0263] Attorney Docket No.: 51796-006WO3

[0264] MGH Ref.: 2025-018

[0265] OTHER EMBODIMENTS

[0266] While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure come within known or customary practice within the art to which the invention pertains and may be applied to the essential features hereinbefore set forth.

[0267] All publications, patents, and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

[0268] Some embodiments of the technology described herein can be defined according to any of the following numbered embodiments:

[0269] E1. A method of treating a subject having hypogonadotropic hypogonadism (HH), the method comprising administering to the subject between about 0.9 pg / kg to about 13.19 pg / kg kisspeptin- 10 or a pharmaceutically acceptable salt thereof, wherein the administration is pulsatile at a frequency of between about 1 hour to about 4 hours, wherein the pulsatile administration is subcutaneous, and wherein the pulsatile administration is over a period of at least 14 days. E2. The method of E1 , wherein the subject is a male.

[0270] E3. The method of E1 , wherein the subject is a female.

[0271] E4. The method of any one of E1-E3, wherein the HH is congenital HH.

[0272] E5. The method of E4, wherein the congenital HH is idiopathic HH (IHH).

[0273] E6. The method of E5, wherein the IHH is Kallmann syndrome.

[0274] E7. The method of any one of E1 -E3, wherein the HH is acquired HH.

[0275] E8. The method of E7, wherein the acquired HH is hypothalamic amenorrhea.

[0276] E9. The method of any one of E1 -E8, wherein the kisspeptin- 10 or a pharmaceutically acceptable salt thereof is administered at a dose of between about 3 pg / kg to about 13.19 pg / kg.

[0277] E10. The method of E9, wherein the kisspeptin- 10 or a pharmaceutically acceptable salt thereof is administered at a dose of between about 7 pg / kg to about 13.19 pg / kg.

[0278] E11. The method of E10, wherein the kisspeptin- 10 or a pharmaceutically acceptable salt thereof is administered at a dose of about 10 pg / kg.

[0279] E12. The method of any one of E1 -E8, wherein the kisspepti n- 10 or a pharmaceutically acceptable salt thereof is administered at a dose of between about 1.5 to about 2.5 pg / kg.

[0280] E13. The method of E12, wherein the kisspepti n- 10 or a pharmaceutically acceptable salt thereof is administered at a dose of about 2 pg / kg.

[0281] E14. The method of any one of E1 -E13, wherein the pulsatile administration is over a period of 14 days.

[0282] E15. The method of any one of E1-E13, wherein the pulsatile administration is over a period of 15 days or longer.

[0283] E16. The method of any one of E1 -E15, wherein the kisspepti n- 10 or a pharmaceutically acceptable salt thereof is administered using a pump.PATENT

[0284] Attorney Docket No.: 51796-006WO3

[0285] MGH Ref.: 2025-018

[0286] E17. The method of any one of E1 -E16, wherein, prior to treatment with kisspeptin- 10 or a pharmaceutically acceptable salt thereof, the subject is administered gonadotropin-releasing hormone (GnRH) or an agonist thereof.

[0287] E18. The method of E17, wherein GnRH is administered at a dose of between about 20 ng / kg to about 30 ng / kg.

[0288] E19. The method of E18, wherein GnRH is administered at a dose of about 25 ng / kg.

[0289] E20. The method of any one of E17-E19, wherein GnRH is administered subcutaneously using a pump.

[0290] E21 . The method of any one of E17-E20, wherein GnRH is administered at a frequency of about every 2 hours.

[0291] E22. The method of any one of E17-E21 , wherein GnRH is administered over a period of about 6 days.

[0292] E23. The method of E17, wherein the GnRH agonist is leuprolide acetate.

[0293] E24. The method of E23, wherein leuprolide acetate is administered at a dose of about 0.5 mg to about 1 .5 mg.

[0294] E25. The method of E24, wherein leuprolide acetate is administered at a dose of about 1 .0 mg.

[0295] E26. The method of any one of E23-E25, wherein leuprolide acetate is administered subcutaneously. E27. The method of any one of E23-E26, wherein leuprolide acetate is administered within two weeks prior to treatment with kisspepti n- 10 or a pharmaceutically acceptable salt thereof.

[0296] E28. The method of any one of E1 -E27, wherein administration of kisspeptin- 10 or a pharmaceutically acceptable salt thereof results in an increase in luteinizing hormone (LH) levels in the subject relative to a pre-treatment baseline LH level.

[0297] E29. The method of any one of E1 -E28, wherein administration of kisspeptin- 10 or a pharmaceutically acceptable salt thereof initiates pulsatile LH secretion in the subject.

[0298] E30. The method of any one of E1-E29, wherein LH levels in the subject remain elevated relative to a pre-treatment baseline LH level for at least one day following cessation of administration of kisspeptin- 10 or a pharmaceutically acceptable salt thereof.

[0299] E31 . The method of any one of E1 -E30, wherein administration of kisspeptin- 10 or a pharmaceutically acceptable salt thereof results in an increase in follicle-stimulating hormone (FSH) levels in the subject relative to a pre-treatment baseline FSH level.

[0300] E32. The method of any one of E1 -E31 , wherein FSH levels in the subject remain elevated relative to a pre-treatment baseline FSH level for at least one day following cessation of administration of kisspeptin- 10 or a pharmaceutically acceptable salt thereof.

[0301] E33. A method for inducing follicular growth in a human female subject having HH, comprising administering kisspeptin- 10 or a pharmaceutically acceptable salt thereof at a dose of between about 0.9 ng / kg to about 13.19 pig / kg, wherein the dose is sufficient to promote development of at least one dominant ovarian follicle in the human female subject.

[0302] E34. The method of E33, wherein the HH is congenital HH.

[0303] E35. The method of E34, wherein the congenital HH is idiopathic HH (IHH).PATENT

[0304] Attorney Docket No.: 51796-006WO3

[0305] MGH Ref.: 2025-018

[0306] E36. The method of E35, wherein the IHH is Kallmann syndrome.

[0307] E37. The method of E33, wherein the HH is acquired HH.

[0308] E38. The method of E37, wherein the acquired HH is hypothalamic amenorrhea.

[0309] E39. The method of any one of E33-E38, wherein the dominant ovarian follicle produces a preovulatory estradiol surge.

[0310] E40. The method of any one of E33-E39, wherein administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof results in ovulation of the dominant ovarian follicle. E41. The method of any one of E33-E40, wherein the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered at a dose of between about 3 pg / kg to about 13.19 pg / kg.

[0311] E42. The method of E41 , wherein the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered at a dose of between about 7 pg / kg to about 13.19 pg / kg.

[0312] E43. The method of E42, wherein the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered at a dose of about 10 pg / kg.

[0313] E44. The method of any one of E33-E40, wherein the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered at a dose of between about 1.5 pg / kg to about 2.5 pg / kg.

[0314] E45. The method of E44, wherein the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered at a dose of about 2 pg / kg.

[0315] E46. The method of any one of E33-E45, wherein the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered subcutaneously.

[0316] E47. The method of any one of E33-E46, wherein the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered using a pump.

[0317] E48. The method of any one of E33-E47, wherein the administration is pulsatile at a frequency of between about 1 hour to about 4 hours.

[0318] E49. The method of any one of E33-E48, wherein the administration is over a period of at least 14 days.

[0319] E50. The method of any one of E33-E49, further comprising monitoring follicular size and estradiol levels to adjust dosing during treatment.

[0320] E51. The method of any one of E33-E50, wherein, following administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof, the dominant ovarian follicle reaches a diameter of at least 12 mm.

[0321] E52. The method of any one of E33-E51 , wherein, following administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof, the subject achieves a serum estradiol concentration of at least 300 pg / mL.

[0322] E53. The method of any one of E33-E52, wherein, following administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof, the subject exhibits vaginal bleeding.

[0323] E54. A method of treating a subject having IHH, the method comprising administering to the subject between about 3 pg / kg to about 13.19 pg / kg kisspeptin-10 or a pharmaceutically acceptable salt thereof, wherein the administration is pulsatile at a frequency of between about 1 hour to about 4PATENT

[0324] Attorney Docket No.: 51796-006WO3

[0325] MGH Ref.: 2025-018

[0326] hours, wherein the pulsatile administration is subcutaneous, and wherein the pulsatile administration is over a period of at least 14 days.

[0327] E55. The method of E54, wherein the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered at a dose of between about 7 pg / kg to about 13.19 pg / kg.

[0328] E56. The method of E55, wherein the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered at a dose of about 10 pg / kg.

[0329] E57. The method of any one of E54-E56, wherein the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered using a pump.

[0330] E58. The method of any one of E54-E57, wherein administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof results in an increase in LH levels in the subject relative to a pre-treatment baseline LH level.

[0331] E59. The method of any one of E54-E58, wherein administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof initiates pulsatile LH secretion in the subject.

[0332] E60. The method of any one of E54-E59, wherein LH levels in the subject remain elevated relative to a pre-treatment baseline LH level for at least one day following cessation of administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof.

[0333] E61. The method of any one of E54-E60, wherein administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof results in an increase in FSH levels in the subject relative to a pre-treatment baseline FSH level.

[0334] E62. The method of any one of E54-E61 , wherein FSH levels in the subject remain elevated relative to a pre-treatment baseline FSH level for at least one day following cessation of administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof.

[0335] E63. The method of any one of E54-E62, wherein the subject is a male.

[0336] E64. The method of any one of E54-E62, wherein the subject is a female.

[0337] E65. The method of E64, wherein the method induces follicular growth in the subject.

[0338] E66. The method of E64 or E65, wherein the method promotes development of at least one dominant ovarian follicle in the subject.

[0339] E67. The method of E66, wherein the dominant ovarian follicle produces a pre-ovulatory estradiol surge.

[0340] E68. The method of E67, wherein administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof results in ovulation of the dominant ovarian follicle.

[0341] E69. The method of any one of E66-E68, wherein, following administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof, the dominant ovarian follicle reaches a diameter of at least 12 mm.

[0342] E70. The method of any one of E64-E69, wherein, following administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof, the subject achieves a serum estradiol concentration of at least 300 pg / mL.

[0343] E71. The method of any one of E64-E70, wherein, following administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof, the subject exhibits vaginal bleeding.PATENT

[0344] Attorney Docket No.: 51796-006WO3

[0345] MGH Ref.: 2025-018

[0346] E72. A method of treating a subject having hypothalamic amenorrhea, the method comprising administering to the subject between about 1 .5 pg / kg to about 2.5 pg / kg kisspeptin-10 or a pharmaceutically acceptable salt thereof, wherein the administration is pulsatile at a frequency of between about 1 hour to about 4 hours, wherein the pulsatile administration is subcutaneous, and wherein the pulsatile administration is over a period of at least 14 days.

[0347] E73. The method of E72, wherein the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered at a dose of about 2 pg / kg.

[0348] E74. The method of E72 or E73, wherein the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered using a pump.

[0349] E75. The method of any one of E72-E74, wherein administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof results in an increase in LH levels in the subject relative to a pre-treatment baseline LH level.

[0350] E76. The method of any one of E72-E75, wherein administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof initiates pulsatile LH secretion in the subject.

[0351] E77. The method of any one of E72-E76, wherein LH levels in the subject remain elevated relative to a pre-treatment baseline LH level for at least one day following cessation of administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof.

[0352] E78. The method of any one of E72-E77, wherein administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof results in an increase in FSH levels in the subject relative to a pre-treatment baseline FSH level.

[0353] E79. The method of any one of E72-E78, wherein FSH levels in the subject remain elevated relative to a pre-treatment baseline FSH level for at least one day following cessation of administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof.

[0354] E80. The method of any one of E72-E79, wherein the subject is a male.

[0355] E81. The method of any one of E72-E79, wherein the subject is a female.

[0356] E82. The method of E81 , wherein the method induces follicular growth in the subject.

[0357] E83. The method of E81 or E82, wherein the method promotes development of at least one dominant ovarian follicle in the subject.

[0358] E84. The method of E83, wherein the dominant ovarian follicle produces a pre-ovulatory estradiol surge.

[0359] E85. The method of E84, wherein administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof results in ovulation of the dominant ovarian follicle.

[0360] E86. The method of any one of E83-E85, wherein, following administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof, the dominant ovarian follicle reaches a diameter of at least 12 mm.

[0361] E87. The method of any one of E81-E86, wherein, following administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof, the subject achieves a serum estradiol concentration of at least 300 pg / mL.PATENT

[0362] Attorney Docket No.: 51796-006WO3

[0363] MGH Ref.: 2025-018

[0364] E88. The method of any one of E81 -E87, wherein, following administration of kisspeptin- 10 or a pharmaceutically acceptable salt thereof, the subject exhibits vaginal bleeding.

[0365] E89. A treatment kit comprising:

[0366] (a) kisspeptin-10 or a pharmaceutically acceptable salt thereof; and

[0367] (b) instructions for administering the kisspeptin-10 or a pharmaceutically acceptable salt thereof subcutaneously in a pulsatile manner at a dose of between about 0.9 pg / kg to about 13.19 pg / kg over a period of at least 14 days to treat HH.

[0368] E90. Kisspeptin-10 or a pharmaceutically acceptable salt thereof for use in the treatment of HH in a human subject, wherein the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered subcutaneously in a pulsatile manner at a dose of between about 0.9 pg / kg to about 13.19 pg / kg, wherein the pulsatile administration has a frequency of about 1 hour to about 4 hours, and wherein the administration is over a period of at least 14 days.

[0369] E91. Use of kisspeptin-10 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of HH in a human subject, wherein the medicament is formulated for subcutaneous, pulsatile administration at a dose of between about 0.9 pg / kg to about 13.19 pg / kg, wherein the pulsatile administration has a frequency of about 1 hour to about 4 hours, and wherein the medicament is administered over a period of at least 14 days.

[0370] E92. Kisspeptin-10 or a pharmaceutically acceptable salt thereof for use in inducing follicular development in a human female subject having HH, wherein the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered subcutaneously in a pulsatile manner at a dose of between about 0.9 pg / kg to about 13.19 pg / kg, wherein the pulsatile administration has a frequency of about 1 hour to about 4 hours, and wherein the administration is over a period of at least 14 days, thereby promoting development of at least one dominant ovarian follicle.

[0371] E93. Use of kisspeptin-10 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for inducing follicular development in a human female subject having HH, wherein the medicament is formulated for subcutaneous, pulsatile administration at a dose of between about 0.9 pg / kg to about 13.19 pg / kg, wherein the pulsatile administration has a frequency of about 1 hour to about 4 hours, and wherein administration over a period of at least 14 days promotes development of at least one dominant ovarian follicle.

[0372] E94. The use of E93, wherein administration of the medicament results in a pre-ovulatory estradiol surge.

[0373] E95. The use of E94, wherein, following administration of the medicament, the subject achieves a serum estradiol concentration of at least 300 pg / mL.

[0374] E96. The use of any one of E90-E95, wherein the kisspeptin-10 or a pharmaceutically acceptable salt thereof or the medicament is administered using a pump.

[0375] Other embodiments are within the following claims.

Claims

PATENTAttorney Docket No.: 51796-006WO3MGH Ref.: 2025-018CLAIMS1. A method of treating a subject having hypogonadotropic hypogonadism (HH), the method comprising administering to the subject between about 0.9 pg / kg to about 13.19 pg / kg kisspeptin-10 or a pharmaceutically acceptable salt thereof, wherein the administration is pulsatile at a frequency of between about 1 hour to about 4 hours, wherein the pulsatile administration is subcutaneous, and wherein the pulsatile administration is over a period of at least 14 days.

2. The method of claim 1 , wherein the subject is a male.

3. The method of claim 1 , wherein the subject is a female.

4. The method of claim 1 , wherein the HH is congenital HH.

5. The method of claim 4, wherein the congenital HH is idiopathic HH (IHH).

6. The method of claim 5, wherein the IHH is Kallmann syndrome.

7. The method of claim 1 , wherein the HH is acquired HH.

8. The method of claim 7, wherein the acquired HH is hypothalamic amenorrhea.

9. The method of claim 1 , wherein the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered at a dose of between about 3 pg / kg to about 13.19 pg / kg.

10. The method of claim 9, wherein the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered at a dose of between about 7 pg / kg to about 13.19 pg / kg.

11. The method of claim 10, wherein the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered at a dose of about 10 pg / kg.

12. The method of claim 1 , wherein the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered at a dose of between about 1.5 pg / kg to about 2.5 pg / kg.

13. The method of claim 12, wherein the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered at a dose of about 2 pg / kg.

14. The method of claim 1 , wherein the pulsatile administration is over a period of 14 days.

15. The method of claim 1 , wherein the pulsatile administration is over a period of 15 days or longer.PATENTAttorney Docket No.: 51796-006WO3MGH Ref.: 2025-01816. The method of claim 1 , wherein the kisspepti n- 10 or a pharmaceutically acceptable salt thereof is administered using a pump.

17. The method of claim 1 , wherein, prior to treatment with kisspeptin- 10 or a pharmaceutically acceptable salt thereof, the subject is administered gonadotropin-releasing hormone (GnRH) or an agonist thereof.

18. The method of claim 17, wherein GnRH is administered at a dose of between about 20 ng / kg to about 30 ng / kg.

19. The method of claim 18, wherein GnRH is administered at a dose of about 25 ng / kg.

20. The method of claim 17, wherein GnRH is administered subcutaneously using a pump.

21. The method of claim 17, wherein GnRH is administered at a frequency of about every 2 hours.

22. The method of claim 17, wherein GnRH is administered over a period of about 6 days.

23. The method of claim 17, wherein the GnRH agonist is leuprolide acetate.

24. The method of claim 23, wherein leuprolide acetate is administered at a dose of about 0.5 mg to about 1.5 mg.

25. The method of claim 24, wherein leuprolide acetate is administered at a dose of about 1 .0 mg.

26. The method of claim 23, wherein leuprolide acetate is administered subcutaneously.

27. The method of claim 23, wherein leuprolide acetate is administered within two weeks prior to treatment with kisspeptin-10 or a pharmaceutically acceptable salt thereof.

28. The method of claim 1 , wherein administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof results in an increase in luteinizing hormone (LH) levels in the subject relative to a pre-treatment baseline LH level.

29. The method of claim 1 , wherein administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof initiates pulsatile LH secretion in the subject.PATENTAttorney Docket No.: 51796-006WO3MGH Ref.: 2025-01830. The method of claim 1 , wherein LH levels in the subject remain elevated relative to a pre-treatment baseline LH level for at least one day following cessation of administration of kisspeptin- 10 or a pharmaceutically acceptable salt thereof.

31. The method of claim 1 , wherein administration of kisspeptin- 10 or a pharmaceutically acceptable salt thereof results in an increase in follicle-stimulating hormone (FSH) levels in the subject relative to a pre-treatment baseline FSH level.

32. The method of claim 1 , wherein FSH levels in the subject remain elevated relative to a pre-treatment baseline FSH level for at least one day following cessation of administration of kisspeptin- 10 or a pharmaceutically acceptable salt thereof.

33. A method for inducing follicular growth in a human female subject having HH, comprising administering kisspeptin-10 or a pharmaceutically acceptable salt thereof at a dose of between about 0.9 pg / kg to about 13.19 pg / kg, wherein the dose is sufficient to promote development of at least one dominant ovarian follicle in the human female subject.

34. The method of claim 33, wherein the HH is congenital HH.

35. The method of claim 34, wherein the congenital HH is IHH.

36. The method of claim 35, wherein the IHH is Kallmann syndrome.

37. The method of claim 33, wherein the HH is acquired HH.

38. The method of claim 37, wherein the acquired HH is hypothalamic amenorrhea.

39. The method of claim 33, wherein the dominant ovarian follicle produces a pre-ovulatory estradiol surge.

40. The method of claim 33, wherein administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof results in ovulation of the dominant ovarian follicle.

41. The method of claim 33, wherein the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered at a dose of between about 3 pg / kg to about 13.19 pg / kg.

42. The method of claim 41 , wherein the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered at a dose of between about 7 pg / kg to about 13.19 pg / kg.PATENTAttorney Docket No.: 51796-006WO3MGH Ref.: 2025-01843. The method of claim 42, wherein the kisspeptin- 10 or a pharmaceutically acceptable salt thereof is administered at a dose of about 10 pg / kg.

44. The method of claim 33, wherein the kisspeptin- 10 or a pharmaceutically acceptable salt thereof is administered at a dose of between about 1.5 pg / kg to about 2.5 pg / kg.

45. The method of claim 44, wherein the kisspeptin- 10 or a pharmaceutically acceptable salt thereof is administered at a dose of about 2 pg / kg.

46. The method of claim 33, wherein the kisspeptin- 10 or a pharmaceutically acceptable salt thereof is administered subcutaneously.

47. The method of claim 46, wherein the kisspeptin- 10 or a pharmaceutically acceptable salt thereof is administered using a pump.

48. The method of claim 33, wherein the administration is pulsatile at a frequency of between about 1 hour to about 4 hours.

49. The method of claim 33, wherein the administration is over a period of at least 14 days.

50. The method of claim 33, further comprising monitoring follicular size and estradiol levels to adjust dosing during treatment.

51. The method of claim 33, wherein, following administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof, the dominant ovarian follicle reaches a diameter of at least 12 mm.

52. The method of claim 33, wherein, following administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof, the subject achieves a serum estradiol concentration of at least 300 pg / mL.

53. The method of claim 33, wherein, following administration of kisspeptin-10 or a pharmaceutically acceptable salt thereof, the subject exhibits vaginal bleeding.

54. A treatment kit comprising:(a) kisspeptin-10 or a pharmaceutically acceptable salt thereof; and(b) instructions for administering the kisspeptin-10 or a pharmaceutically acceptable salt thereof subcutaneously in a pulsatile manner at a dose of between about 0.9 pg / kg to about 13.19 pg / kg over a period of at least 14 days to treat HH.PATENTAttorney Docket No.: 51796-006WO3MGH Ref.: 2025-01855. Kisspepti n-10 or a pharmaceutically acceptable salt thereof for use in the treatment of HH in a human subject, wherein the kisspeptin- 10 or a pharmaceutically acceptable salt thereof is administered subcutaneously in a pulsatile manner at a dose of between about 0.9 pg / kg to about 13.19 pg / kg, wherein the pulsatile administration has a frequency of between about 1 hour to about 4 hours, and wherein the administration is over a period of at least 14 days.

56. Use of kisspeptin- 10 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of HH in a human subject, wherein the medicament is formulated for subcutaneous, pulsatile administration at a dose of between about 0.9 pg / kg to about 13.19 pg / kg, wherein the pulsatile administration has a frequency of between about 1 hour to about 4 hours, and wherein the medicament is administered over a period of at least 14 days.

57. Kisspeptin- 10 or a pharmaceutically acceptable salt thereof for use in inducing follicular development in a human female subject having HH, wherein the kisspeptin-10 or a pharmaceutically acceptable salt thereof is administered subcutaneously in a pulsatile manner at a dose of between about 0.9 pg / kg to about 13.19 pg / kg, wherein the pulsatile administration has a frequency of between about 1 hour to about 4 hours, and wherein the administration is over a period of at least 14 days, thereby promoting development of at least one dominant ovarian follicle.

58. Use of kisspeptin-10 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for inducing follicular development in a human female subject having HH, wherein the medicament is formulated for subcutaneous, pulsatile administration at a dose of between about 0.9 pg / kg to about 13.19 pg / kg, wherein the pulsatile administration has a frequency of between about 1 hour to about 4 hours, and wherein administration over a period of at least 14 days promotes development of at least one dominant ovarian follicle.

59. The use of claim 58, wherein administration of the medicament results in a pre-ovulatory estradiol surge.

60. The use of claim 59, wherein, following administration of the medicament, the subject achieves a serum estradiol concentration of at least 300 pg / mL.

61. The use of any one of claims 55-58, wherein the kisspeptin-10 or a pharmaceutically acceptable salt thereof or the medicament is administered using a pump.